Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

These are some of the problems that doctors have encountered in China’s public hospitals. They have been speaking out in recent weeks, questioning the quality of the country’s drugs and urging reform ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the ... 2024 forecasts for the drug, but reined them in again ...

With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).

Delhi, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The recent approval of sacituzumab tirumotecan in China represents a significant advancement in oncology, particularly in the realm of targeted therapies. This ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only ...

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the ...